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Abstract
Background: Like all tripartite motif (TRIM) proteins, the retroviral restriction factor TRIM5a consists of RING, B-box
2 and coiled-coil domains, with a C-terminal B30.2(SPRY) domain. Although structures have been determined for
some individual TRIM domains, the structure of an intact TRIM protein is unknown.
Results: Here, we express and characterize a protease-resistant 29-kD core fragment containing the B-box 2, coiled
coil and adjacent linker (L2) region of TRIM5a. This BCCL2 protein formed dimers and higher-order oligomers in
solution. Approximately 40% of the BCCL2 secondary structure consisted of alpha helices. Partial loss of alpha-
helical content and dissociation of dimers occurred at 42°C, with the residual alpha helices remaining stable up to
80°C.
Conclusions: These results indicate that the B-box 2, coiled-coil and linker 2 regions of TRIM5a form a core
dimerization motif that exhibits a high level of alpha-helical content.
Background
Soon after entry into the cells of certain mammalian
species, some retroviruses encounter blocks mediated by
the restriction factor TRIM5a. For example, human
immunodeficiency virus (HIV-1), the causative agent of
acquired immunodeficiency syndrome (AIDS), can infect
human and chimpanzee cells, but is blocked in cells of
Old World monkeys [1-5]. In contrast, simian immuno-
deficiency virus (SIVmac) infects Old World monkey
cells but is restricted in the cells of most New World
monkeys [3,6]. TRIM5a, a member of the tripartite
motif (TRIM) family of proteins, mediates these early
infection blocks [7-12]. Differences in TRIM5a proteins
among species account for the distinct patterns of retro-
viral restriction observed in mammalian lineages
[5,7-12]. TRIM5a has been shown to bind and promote
the premature uncoating of incoming retroviral capsids
[13-19].
Like all TRIM proteins, TRIM5a contains RING,
B-box 2 and coiled coil domains [20,21]. The a isoform
of TRIM5, which is the only TRIM5 isoform that exhi-
bits antiretroviral activity [7], also has a carboxy-
terminal B30.2(SPRY) domain [20,21]. Mutagenic studies
have shed light on the contribution of the TRIM5a
domains to antiretroviral activity. The RING domain,
which exhibits E3 ubiquitin ligase activity, contributes to
anti-HIV-1 potency, but is not absolutely required for a
modest level of restriction ability [7,13,22-24]. The B-
box 2 domain is essential for higher-order associations
among TRIM5a dimers and contributes to the coopera-
tive binding of TRIM5a to the retroviral capsid
[14,16,25,26]. The coiled coil and adjacent linker (L2)
region are sufficient for dimerization of TRIM5a,w h i c h
results in a higher avidity of TRIM5a-capsid binding
[27-30]. The direct contact between TRIM5a and the
retroviral capsid is thought to be mediated by the B30.2
(SPRY) domain. Surface-exposed loops within the
TRIM5a B30.2(SPRY) domain exhibit pronounced varia-
bility and have been subject to positive selection during
mammalian evolution [31-36]. Amino acid changes in
these B30.2(SPRY) variable loops or in the viral capsid
protein can alter capsid recognition and the specificity
of retrovirus restriction [15,23,33,37-47].
Structural information on TRIM proteins is still lim-
ited. There are no published structures of a complete
TRIM protein, even though some TRIM proteins (e.g.,
TRIM19 (promyelocytic leukemia (PML) protein),
TRIM20 (pyrin), TRIM18 (MID1), TRIM21 (Rho/SSA))
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to their association with human diseases [48-54]. Poor
expression levels and tendencies to aggregate into
nuclear or cytoplasmic bodies have hampered efforts to
obtain complete TRIM protein structures [20,21]. None-
theless, structures of individual TRIM domains have
been solved. The RING and B-box 2 structures of
TRIM5 and other TRIM proteins have been solved by
NMR [16,55-59]. Structures of the B30.2(SPRY) domains
of TRIM21 as well as of several proteins not in the
TRIM family have been obtained by x-ray crystallogra-
phy [60-64]. No structural information on the coiled-
coil domain of any TRIM protein is available. Such
information would be very valuable, as the coiled coil
presumably resides near the dimeric axis and provides a
central scaffold for the positioning of the other TRIM
domains. The TRIM coiled coil is predicted to be alpha
helical [65-67], but lacks easily identifiable heptad repeat
motifs that characterize some of the classical coiled coils
for which structural information is available.
Recently, we have devised approaches that allow expres-
sion of sufficient quantities of TRIM5a variants in baculo-
virus-infected cells for purification and biochemical
characterization [28,29]. Substitution of the TRIM21
RING domain for that of rhesus monkey TRIM5a resulted
in a protein (TRIM5-21R) that was efficiently expressed
and was purified. TRIM5-21R is a dimer and binds HIV-1
capsid-nucleocapsid (CA-NC) complexes assembled in
vitro[28,29]. Binding of TRIM5-21R to HIV-1 CA-NC
complexes depends upon the B30.2(SPRY) domain v1 vari-
able region. Protease-resistant fragments of TRIM5-21R
were characterized [28]. Here we describe the expression
in E. coli, purification and characterization of one such
fragment containing the B-box, coiled coil and linker 2
(L2) region of rhesus monkey TRIM5a.
Methods
Plasmid construction and production of recombinant
BCCL2 protein
The recombinant bacterial construct expressing BCCL2
was prepared using the Champion pET Gateway vector
with a kanamycin cassette(Invitrogen). Gateway recom-
bination resulted in a gene that encodes an N-terminal
hexa-histidine tag, a spacer, and the BCCL2 protein.
The predicted N-terminus of the resulting BCCL2 pro-
tein is HHHHHHGSGLVPRGSASMSDSEVNQEAKP
EVKLSPEEGQK.... The recombinant vector was trans-
formed into BL21(DE3)pLysS competent cells (Invitro-
gen). Five single colonies were picked and examined for
expression. The colony exhibiting the highest level of
BCCL2 expression was incubated in Luria Broth (LB) at
37°C till the OD reached 0.8, at which time isopropyl-
thiogalactoside (IPTG) was added to a final concentra-
tion of 1 mM; incubation was continued overnight
at 18°C. The cDNAs expressing the wild-type BCCL2
protein and B-box 2 mutants were cloned into pcDNA/
V5-GW/D-TOPO (Invitrogen) for expression in mam-
malian cells.
Expression and purification of the BCCL2 proteins
Single bacterial colonies were expanded and induced as
described above. The cells were harvested by centrifuga-
tion at 4,000 × g for 10 minutes, rinsed in phosphate-
buffered saline, and resuspended at 2.5 × 10
7 cells/ml in
Bacterial Protein Extraction Reagent (BPER) (Pierce Bio-
technology) in the presence of 1 mM dithiothreitol
(DTT) and a cocktail of protease inhibitors comprising
10 mM (amidinophenyl)-methanesulfonyl fluoride
(APMSF), 10 mM E-64, 10 mM leupeptin, and 1 mM
pepstatin A (final concentrations). A sample was taken
for analysis, and then the cell debris and nuclei were
removed by centrifugation at 4,000 × g for 10 minutes.
The resulting cell supernatant was mixed with Ni
+2-
nitrilotriacetic acid (NTA) superflow resin (Qiagen)
according to the manufacturer’s protocol. Protein was
eluted from the resin with 300 mM imidazole. The
eluted protein fraction was concentrated and was loaded
on a Superdex 200 HR 10/30 size-exclusion chromato-
graphy (SEC) column (GE Healthcare). The column was
equilibrated against PBS. Preparative SEC was run at
0.2 ml/min at 4°C. A calibration curve for molecular size
estimation was generated by loading gel-filtration mar-
kers (Biorad) comprising thyroglobulin (667 kD), bovine
gamma-globulin (158 kD), chicken ovalbumin (44 kD),
equine myoglobin (17 kD) and Vitamin B12 (1.35 kD)
proteins onto this SEC column and eluting under similar
conditions. The resulting fractions were analyzed by
SDS-PAGE and those containing the BCCL2 protein
were pooled and concentrated. For further purification,
buffer was exchanged into 20 mM Tris-HCl/50 mM
NaCl, pH 8 by using a PD-10 column (Pharmacia).
Anion-exchange chromatography was subsequently per-
formed on a 5-ml Q-Sepharose Hi-Trap column (GE
Healthcare) equilibrated with 20 mM Tris-HCl/50 mM
NaCl, pH 8.0. Bound proteins were eluted by using a
NaCl gradient (50 to 750 mM NaCl in 20 mM Tris-HCl,
pH 8.0). The BCCL2 protein was eluted with 400 mM
NaCl, and fractions containing the protein were pooled,
dialyzed and concentrated by ultrafiltration with Centri-
con-10 devices (Amicon). The cocktail of protease inhibi-
tors (at the concentrations referred to above) was added
to the samples throughout each stage of the purification
scheme. The BCCL2 protein was at least 95% pure, as
determined by a Coomassie-stained gel.
Elicitation of polyclonal antibodies in rabbits
Polyclonal antibodies directed against the purified LLER
protein were raised in rabbits by Open Biosystems
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100 μg of protein in Complete Freund’sA d j u v a n ta n d
boosted twice with 50 μg protein in Incomplete Freund’s
Adjuvant.
Western blotting
Aliquots were collected at each step of BCCL2 purifica-
tion and the associated proteins were resolved by
sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis (SDS-PAGE). The proteins were transferred to poly
(vinylidene fluoride) (PVDF) Immobilon filters (Milli-
pore) by a semidry blotting apparatus. Polyclonal rabbit
antibody directed against the purified BCCL2 protein
was used as the primary antibody to detect the BCCL2
protein in Western blot experiments. Horseradish per-
oxidase (HRP)-conjugated goat anti-rabbit IgG was used
as the secondary antibody. The Western blot was devel-
oped with the ECL chemiluminescence detection system
(GE Healthcare) and the Kodak film processor system
(Kodak).
Analytical size-exclusion chromatography
As a m p l eo ft h eN i
+2-affinity-purified BCCL2 protein
w a sf r a c t i o n a t e db ys i z ee x c l u s i o no naS u p e r d e x2 0 0
(10/30) column calibrated with molecular-weight mar-
kers. The column was equilibrated in PBS at a flow rate
of 0.4 ml/min, and the absorbance of the eluted protein
w a sr e c o r d e da t2 8 0n m .T h ec o l u m nw a sm o u n t e do n
a high-performance liquid chromatography system (Var-
ian Star). Fractions were collected every minute, and a
sample from each fraction was analyzed by SDS-PAGE.
Size-Exclusion Chromatography-Light Scattering (SEC-LS)
The molecular masses of full-length proteins were deter-
mined by Ewa Folta-Stogniew using SEC-LS in the
HHMI Biopolymer Facility and W. M. Keck Foundation
Biotechnology Resource Laboratory at Yale University.
Briefly, a sample containing approximately 300 μgo f
LLER protein was filtered through a 0.22-μmD u r a p o r e
membrane (Millipore) and applied to a Superose 6 HR
10/30 column coupled with an in-line Dawn EOS laser
light-scattering apparatus (Wyatt Technology Corpora-
tion), refractometer (Wyatt Technology), and UV detec-
tor (Waters Corporation). The average molecular mass
of the elution peak was calculated using ASTRA
software.
Mass spectrometry
Matrix-assisted laser desorption ionization-time of flight
(MALDI-TOF) mass spectrometry of the LLER protein
was performed at the Molecular Biology Core Facility at
Dana-Farber Cancer Institute (Boston, MA), using a
sinapinic acid matrix.
Dynamic Light Scattering
Measurements were carried out using a temperature-
controlled Zetasizer Nano-S (Malvern) at 20°C. A pro-
tein solution (0.5 mg/ml) was filtered through a 0.2-μm
membrane into a 20°C pre-warmed light-scattering cuv-
ette and measurements were carried out according to
the manufacturer’s instructions.
Crosslinking of the purified BCCL2 protein
The purified LLER protein (1 mg/ml) was incubated
with various concentrations (final concentrations of 0,
0.25, 0.5, 1 and 1.0 mM) of glutaraldehyde (Sigma) at
room temperature for 8 minutes, after which 0.1 M
Tris-HCl, pH 7.5 was added to quench the reaction.
The crosslinked proteins were boiled in SDS-denaturing
buffer and subjected to SDS-PAGE (4-12% acrylamide)
and Coomassie Blue staining.
Transiently transfected 293 T cells expressing wild-
type rhesus monkey BCCL2 and the corresponding
B-box 2 mutants were washed in phosphate-buffered
saline (PBS) and lysed in NP40 lysis buffer (0.5% Noni-
det P40 (NP40), 1× protease inhibitor (complete EDTA-
free, Roche Diagnostics) in PBS) for 45 minutes at 4°C.
Lysates were centrifuged at 14,000 × g for 15 minutes at
4°C. Lysates were crosslinked with varying concentra-
tions (up to 2 mM) of glutaraldehyde for 8 minutes at
room temperature and centrifuged briefly in a table-top
centrifuge. The reaction mix was quenched with 0.1 M
Tris-HCl, pH 7.5, briefly centrifuged and analyzed by
Western blotting as described above.
Native gel electrophoresis
Electrophoresis was performed using the Novex Polya-
crylamide Gel Electrophoresis System (Invitrogen). Pro-
tein samples were mixed with native gel running buffer
(0.1 M Tris-HCI (pH 8.8), 20% glycerol, and 0.0025%
bromophenol blue) to a final concentration of 0.5 mg/
ml. Thirty microliters of each sample was loaded onto a
4-16% gradient polyacrylamide gel and run at 150 V in
Tris-glycine buffer (0.192 M acetate and 0.25 M Tris at
pH 8.3). After the dye front migrated to the bottom of
the gel, the gel was developed using Coomassie Blue
staining. The unstained NativeMark protein standard
(Invitrogen) was used for markers.
Electron Microscopy
For negative staining, the purified LLER protein was
directly applied to carbon-coated grids after glow dis-
charge. These were negatively stained with 1% (w/v) ura-
nyl formate and observed in a Tecnai G2 Spirit BioTWIN
(FEI Company) electron microscope operated at 100 kV.
Micrographs were recorded at a magnification of 100,000
x and pictures taken under low-dose conditions.
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protein solution was applied to a Quantifoil grid, blotted
by filter paper for 2 seconds and immediately plunged
into liquid ethane; the whole process was performed
with an FEI Vitrobot. The prepared cryo-grids then
were subjected to imaging in a Tecnai F20 field-emis-
s i o ng u ne l e c t r o nm i c r o s c o p ee q u i p p e dw i t haG a t a n
CT3500 cryo-transfer holder that was cooled down to
-180°C by liquid nitrogen. Micrographs were recorded
in bright-field mode at a magnification of 150,000 × and
at a defocus of ~3-5 μmb ya4k×4kG a t a nC C D
camera, with a total dose no greater than 100 electrons
per nm
2.
Circular dichroism (CD) spectroscopy
Samples for circular dichroism (CD) spectroscopy were
buffer-exchanged into PBS. The CD spectrum was mea-
sured with an Aviv 410 CD spectrometer (Aviv Biome-
dical), using a quartz cuvette with a path length of
0.1 cm. Measurements were obtained in 0.5-nm inter-
vals from 195 to 245 nm, a 1-nm bandwidth, and a 0.5-
s measurement time at each wavelength. Instrument
units were converted to mean residue molar ellipticity
according to the formula: θ = millidegree/molar concen-
tration/number of amino acids. The percentage of sec-
ondary structure was calculated using the following
formula: % helicity = 100 × θ222(observed)/θ222(max),
where θ222(max) = -40,000 × [1 - (2.5/number of amino
acid residues)].
Results
Expression and purification of a core fragment of
TRIM5arh
TRIM5-21R is a chimeric protein containing the RING
domain of TRIM21 and the B-box 2, coiled coil, linker
2 and B30.2(SPRY) domain of TRIM5arh [28,29].
TRIM5-21R, like many TRIM proteins [20,21], is prone
to aggregation at high concentrations. To identify con-
structs that might be better behaved, we characterized
TRIM5-21R fragments that were relatively resistant to
trypsin and chymotrypsin digestion [28]. Proteins corre-
sponding to these protease-resistant fragments were
expressed in E. coli. Among the several constructs
tested, the BCCL2 protein was soluble and able to be
purified in adequate amounts following affinity purifica-
tion (Table 1). The BCCL2 protein consists of an N-
terminal His6 tag and a vector-derived spacer fused to
the B-box 2 domain, the coiled-coil domain and the
linker 2 (L2) region of TRIM5arh (
83EVKLSPEE...
MEFRLTDA
296); the predicted molecular weight of the
BCCL2 protein is 29.026 kD. Although the BCCL2 pro-
tein lacks a B30.2(SPRY) domain, which is needed for
HIV-1 capsid binding and virus restriction [7,19,28,29],
it retains the other TRIM5a domains required for
inhibition of HIV-1 infection. The BCCL2 protein with
an N-terminal His6 tag was expressed in the BL21(DE3)
strain of E. coli under the control of the T7 promoter.
Different temperatures, times/duration of induction, and
IPTG concentrations were studied to identify conditions
under which BCCL2 protein expression was maximal,
while maintaining adequate solubility. Optimal condi-
tions involved treatment with 1 mM IPTG at an optical
density of the culture of 0.8 and an overnight induction
at 18°C. Although a significant portion (approximately
60-70%) of the BCCL2 protein remained in the insoluble
pellet, soluble BCCL2 protein (approximately 0.1 mg/
liter of E.coli) was obtained and was affinity purified
using Ni-NTA beads and elution with 250 mM imida-
zole (Figure 1A).
The affinity-purified BCCL2 protein was analyzed by
gel-filtration chromatography (Figure 1B). The BCCL2
protein migrated in overlapping broad peaks at positions
corresponding to molecular weights of approximately 50
- 400 kD. The BCCL2 protein was further purified by
anion-exchange chromatography, where it eluted in a
single peak (Figure 1C). The purified protein fractions
(fractions 24 to 27) were pooled, concentrated and
stored at 4°C (short-term) or at -20°C at concentrations
less than 0.5 mg/ml (long-term).
Effects of B-box 2 changes on BCCL2 expression and
oligomerization
The self-association of TRIM5a dimers in higher-order
complexes is dependent upon specific charged and
hydrophobic residues on the surface of the B-box 2
domain [16,26]. To investigate whether TRIM5a self-
association might contribute to the behavior of the
BCCL2 protein, we altered B-box 2 residues previously
shown to contribute to higher-order association [16,26]
Table 1 Expression and solubility of rhesus monkey
TRIM5a variants in E. coli
Construct
a Soluble
b Inclusion Body
b
Full-length TRIM5a ++
RBCC - +++++
RBCCL2 +/- ++
RING-BCCL2 - +
BCC - +++
BCCL2 +++ ++++
aThe rhesus monkey TRIM5a variants are designated according to the
domains included in the protein: R = RING domain; B = B-box 2 domain; CC =
coiled-coil domain; L2 = linker 2 region. All of the TRIM5a constructs were
expressed in BL21(DE3)pLysS E. coli using the Champion pET Gateway vector,
which adds an N-terminal hexa-histidine tag and a spacer. The inserted
fragment of the RBCCL2 protein corresponds to the TRIM5arh sequences
1MASGILL...MEFRLTDA
296. The inserted fragment of the RING-BCCL2 protein
corresponds to the TRIM5arh sequences
15CPICLE...MEFRLTDA
296.
bThe amount of protein found in the soluble and insoluble (inclusion body)
fractions is indicated, with increased levels designated by increasing numbers
of plus signs.
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BCCL2 protein that could be solubilized resulted from
the changes in the B-box 2 domain (Figure 2). The
expression level of soluble B-box mutant proteins such
as LLER was approximately 1-2 mg/liter of E.coli. The
B-box 2 mutants (LLWL and LLER) with multiple sur-
face changes eluted as two major peaks on a gel-
filtration column, in contrast to the broad peak observed
for the wild-type BCCL2 protein (Figure 3). The LLER
protein demonstrated the clearest separation into two
peaks of approximately 170 and 400 kD.
Effect of zinc on LLER expression and oligomerization
Because the B-box 2 domain of the BCCL2 protein
binds two zinc ions [16], we investigated the effect of
zinc supplementation and DTT treatment on the
expression and oligomerization of the LLER variant. No
augmentation of LLER expression resulted from
Figure 1 Purification of the BCCL2 protein expressed in bacteria. A. Bacterial cells expressing the BCCL2 protein were lysed and the
homogenates subjected to purification approaches. In lane 1, the soluble BCCL2 protein was purified by Ni
+2-NTA metal-affinity
chromatography. Lane 2 shows the insoluble pellet obtained after lysis of the bacteria with lysis buffer. The proteins in each sample were
resolved by SDS-PAGE and Coomassie Blue staining. B. The affinity-purified BCCL2 protein was loaded onto a gel-filtration column and eluted at
a flow rate of 0.3 ml/min. The OD280 of the eluted protein is plotted (blue line). The profile of the globular protein standards (thyroglobulin (670
kD), bovine gamma-globulin (158 kD), chicken ovalbumin (44 kD), equine myoglobin (17 kD) and vitamin B12 (1.35 kD) is shown in red. Fractions
from the gel-filtration column were separated on a 12% SDS-polyacrylamide gel, which was stained with Coomassie Blue. An aliquot of the
BCCL2 protein sample loaded on the gel-filtration column was analyzed (Load), along with the molecular-weight markers (M). C. The affinity-
purified BCCL2 protein was loaded onto a Hi-trap Q anion-exchange column and eluted at a flow rate of 0.5 ml/min (left panel). The fractions
from the column were separated on a 12% SDS-polyacrylamide gel, which was stained with Coomassie Blue (right panel).
Table 2 B-box 2 variants of the BCCL2 protein
BCCL2 Variant B-box 2 changes
wild-type (wt)
ER E120R, R121E
WL W117E, L118S
WER W117E, E120R, R121E
LLWL L105E, L106E, W117E, L118S
LLER L105E, L106E, E120R, R121E
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ZnCl2;i nf a c t ,L L E Re x p r e s s i o nw a sd i m i n i s h e da tt h e
highest ZnCl2 concentration tested (data not shown).
The addition of ZnCl2 or DTT did not significantly
affect the elution profile of the LLER protein on gel-
filtration chromatography (Figure 4 and data not shown).
Dynamic light scattering analysis of the oligomeric state
of the LLER protein
The oligomeric state of the LLER protein, purified by
nickel-affinity and anion-exchange chromatography, was
investigated by size-exclusion chromatography-light
scattering (SEC-LS). SEC-LS can estimate molecular
mass independently of the Stokes radius of the protein
and without reference to a curve based on protein stan-
dards. Molecular mass determination by SEC-LS
depends only upon the light-scattering and refractive
indices, which are measured by detectors situated down-
stream of the size-exclusion column. The LLER protein
eluted in two peaks, the first ranging from 140-160 kD,
the second from 57-61 kD (Figure 5A). A size analysis
by Astra (Figure 5B) calculated a hydrodynamic radius
of approximately 4.8 nm. The molecular weight of the
p r o t e i ni nP e a k2i sc o n s i s t e n tw i t ht h a te x p e c t e df o ra
Figure 2 Effect of B-box 2 changes on BCCL2 expression and
solubility. The wild-type (wt) BCCL2 protein and the indicated B-
box 2 mutants were expressed in E. coli. The bacteria were lysed
and the lysates centrifuged at 4000 × g for 10 minutes. The
supernatants were loaded onto a Ni
+2-NTA affinity column; the
proteins eluted with 300 mM imidazole were analyzed by SDS-PAGE
and Coomassie Blue staining.
Figure 3 Comparison of the size-exclusion chromatography profiles of the wild-type and mutant BCCL2 proteins. A. Purified wild-type
(wt) and mutant BCCL2 proteins were loaded onto a gel-filtration column and eluted at a flow rate of 0.3 ml/min. The protein peaks 1 (P1) and
2 (P2) are indicated. The positions at which the globular proteins standards thyroglobulin (670 kD) and bovine gamma-globulin (158 kD) were
eluted in a parallel run are indicated. B. Fractions from the gel-filtration column were separated on a 12% SDS-polyacrylamide gel, which was
stained with Coomassie Blue (bottom panel). The 25- and 37-kD molecular weight markers (M) are shown in the left-most lanes. An aliquot of
the LLWL protein loaded on the gel-filtration column was also analyzed (Load). The positions of peaks P1 and P2 are noted.
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sents a higher-order oligomer.
We conducted additional dynamic light-scattering
analysis of the two purified LLER protein fractions from
size-exclusion chromatography (Figure 6). The protein
in Peak 1 exhibited a diameter of 11.6 nm and a poly-
dispersity of 22%, and the protein in Peak 2 exhibited a
diameter of 8.6 nm and a polydispersity of 45%.
Crosslinking analysis of the LLER protein
The oligomeric state of the LLER protein was examined
by chemical crosslinking with glutaraldehyde, followed
by analysis on an SDS-polyacrylamide gel. The major
crosslinked form of the protein migrated around 60 kD,
suggestive of a dimer (Figure 7A). Smaller quantities of
higher-order, approximately 150-kD forms were
observed after crosslinking.
Next, the LLER protein from gel-filtration fractions
(Peaks 1 and 2) were crosslinked with glutaraldehyde
and analyzed. The LLER protein in Peak 2 mainly cross-
linked into dimers. By contrast, the protein in Peak 1
formed fewer dimers and crosslinked primarily into
higher-molecular-weight species (Figure 7B).
Because crosslinked TRIM5 protein can migrate aber-
rantly on SDS-polyacrylamide gels [27-29,68], the LLER
protein crosslinked with glutaraldehyde was analyzed by
mass spectrometry. Most of the untreated LLER
protein exhibited a mass consistent with a monomer
(28,720 Da), with a small amount of dimer (57,700 Da)
(Figure 7C). The LLER protein crosslinked with glutaral-
dehyde demonstrated approximately equivalent amounts
of monomer (31,094 Da) and dimer (61,716 Da) (Figure
7D). These results support the conclusion that the LLER
protein is mainly dimeric, with some higher-order
forms. Approximately half of the LLER protein migrated
on native gels at a size consistent with a dimer, with
most of the remainder of the protein migrating as a
monomer; a small fraction of the protein migrated as a
higher-order oligomer (data not shown).
The oligomeric state of the wild-type BCCL2 protein
was compared with that of the B-box 2 mutants. For
this purposes, the proteins were expressed transiently in
293 FT human kidney cells. Compared with the wild-
type BCCL2 protein, the B-box 2 mutants were
expressed comparably (Figure 8A) and exhibited a simi-
lar pattern upon crosslinking (Figure 8B). Thus, all of
the B-box 2 mutants retain the ability to dimerize.
Circular dichroism (CD) Spectrometry
The CD spectrum of the LLER protein was determined at
different temperatures (Figure 9A). The spectrum is char-
acterized by a large negative change of ellipticity at 222
nm and is typical of that expected for a structured, pre-
dominantly alpha-helical, protein [69]. A quantitative
analysis of the spectra obtained at different temperatures
suggested that an extended alpha-helical conformation
exists over a wide range of temperatures. The stability of
the protein was examined by monitoring the effect of
Figure 4 Effect of zinc and dithiothreitol (DTT) on LLER oligomerization. The LLER protein was applied to a gel-filtration column in the
presence of 25 μM ZnCl2 and the indicated concentrations of DTT and eluted at a flow rate of 0.3 ml/min. The profile of the eluted protein is
shown.
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(Figure 9B). The LLER protein exhibited a biphasic loss
of alpha-helical content, with one transition at 42°C and
another near 80°C. The 42°C transition occurs concomi-
tantly with a dramatic decrease in the dimerization of the
protein, as judged by crosslinking analysis (Figure 9C).
Protease resistance of the BCCL2 protein
The protease resistance of the LLER protein was com-
pared with that of the TRIM5a-21R protein by incubat-
ing the proteins with trypsin. At incubation times where
the TRIM5a-21R was substantially degraded to smaller
fragments by trypsin, the LLER protein was retained in
significant amounts (Figure 10). A major portion of the
LLER protein is resistant to digestion, suggesting that
these fractions are either compactly folded or represent
higher-order oligomers that are resistant to trypsin
digestion.
Electron microscopy of the LLER protein
The purified LLER protein was examined by negative
staining under a transmission electron microscope.
Figure 5 Size-exclusion chromatography-light scattering (SEC-LS) analysis of the LLER protein. A. Approximately 300 μg of the purified
LLER protein was applied to a Superose 6 HR 10/30 column coupled with an in-line Dawn EOS laser light-scattering apparatus, refractometer
and UV detector. The dashed red line represents the light-scattering signal at 90°. The green trace represents the refractive index. The blue trace
represents the UV absorption at 280 nm. B. The solid red line indicates the refractometer trace of Peak 1 (P1) and Peak 2 (P2). The “dots”
represent the weight-average molecular mass for each slice, measured every second. The results of the analysis performed on the protein in
Peak 2 (P2) are shown beneath the figure. The table summarizes the analyses of Peaks 1 and 2.
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Page 8 of 14Figure 6 Dynamic light scattering analysis of the LLER protein. The polydispersity (%Pd) and size (mean and mode, in nm) of the purified
LLER protein were estimated by dynamic light scattering. A 12-μl sample of a 500 μg/ml solution of the LLER protein in peak 1 (A) and peak 2
(B) were analyzed by a temperature-controlled Zetasizer Nano-S dynamic light-scattering instrument at 20°C.
Figure 7 Crosslinking analysis of the LLER protein. A. The LLER protein, purified by nickel-affinity and anion-exchange chromatography, was
incubated with the indicated concentrations (in mM) of glutaraldehyde (GA). The protein was then boiled in Laemmli buffer and analyzed on a
4-12% SDS-polyacrylamide gel. The arrow indicates the positions of the monomers (M), dimers (D) and higher-order oligomers (H-O). B. The peak
1 (P1) and peak 2 (P2) fractions of the LLER protein were purified by gel-filtration chromatography and separately crosslinked by incubation with
the indicated concentrations of glutaraldehyde (GA). The proteins were then analyzed on a 4-12% SDS-polyacrylamide gel. C, D. The LLER
protein was either untreated (C) or crosslinked with glutaraldehyde (D) prior to MALDI-TOF analysis. The molecular mass estimations in daltons
for the single mass ionization peaks are shown.
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Page 9 of 14Figure 8 Oligomerization state of BCCL2 variants in mammalian cells. A. Lysates from 293 T cells expressing the wild-type (wt) and mutant
BCCL2 proteins with V5 epitope tags were analyzed by 12% SDS-PAGE and Western blotted with an HRP-conjugated anti-V5 antibody. B. Lysates
from 293 T cells expressing the wild-type (wt) and mutant BCCL2 proteins were treated with the indicated concentrations of glutaraldehyde and
then boiled in Laemmli buffer and analyzed by SDS-PAGE and Western blotting, as described above. The positions of the molecular-weight
markers in kD are shown. The arrows indicate the positions of monomers (M), dimers (D) and higher-order oligomers (H-O).
Figure 9 Secondary structure and melting temperature of the LLER protein. A. The far-UV spectra (195 - 245 nm) of the LLER protein were
recorded with an Aviv circular dichroism (CD) spectrometer at the indicated temperatures. The percentage of alpha-helical content at the
various temperatures was calculated and is shown in the key. B. The melting curve of the BCCL2 protein was generated by plotting the alpha-
helical content as a function of temperature. Note the biphasic shape of the curve. C. Approximately 2 μg of the BCCL2 protein was incubated
at the indicated temperatures for 5 minutes prior to the addition of 1 mM glutaraldehyde. Incubation at the same temperature was continued
for another 8 minutes, after which the reaction was quenched by addition of excess 0.1 M Tris-HCl, pH 7.5 buffer. A control reaction without the
addition of glutaraldehyde was also performed at each temperature. The reaction mixtures were boiled in Laemmli buffer and analyzed on a
4-12% SDS-polyacrylamide gel. M, molecular weight markers.
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Page 10 of 14Most of the shapes on the grid were round or ovoid,
although occasional filaments were observed (Figure
11A). Single-particle imaging by cryoelectron micro-
scopy was performed on the peak 1 and peak 2 gel-
filtration fractions of the LLER protein. The LLER pro-
teins from peak 1 formed C-shaped structures roughly
120-130 Å wide, with an appendage asymmetrically
placed to one side of the arc (Figure 11B). The LLER
proteins in peak 2 consisted of spherical structures
approximately 105-115 Å in diameter (Figure 11C, panel
1). The addition of antibodies directed against the N-
terminal His6 tag allowed visualization of complexes of
the LLER protein with one antibody molecule (Figure
11C, panel 3) or with two antibody molecules (Figure
11C, panel 4). These results indicate that these struc-
tures represented LLER multimers that were at least
dimeric.
Discussion
Previous studies of the TRIM5a-21R protein suggested
that TRIM5a preferentially forms dimers [28,29]. One
of the major protease-resistant fragments of TRIM5a-
21R consisted of the B-box 2 and coiled-coil domains,
as well as the adjacent linker 2 (L2) region [28]. Here,
we produced this protease-resistant fragment (BCCL2)
of rhesus monkey TRIM5a and verified that it is
relatively resistant to trypsin digestion compared with
the TRIM5a-21R protein. Protease resistance often is
associated with the absence of conformationally flexible
surface loops on a protein and thus might indicate a
propensity to crystallize [70,71]. Although the polydis-
persity of the purified BCCL2 protein is high, an unfa-
vorable predictor of crystallizability [71,72], additional
modifications of the protein, optimization of solvent
conditions or the inclusion of appropriate ligands may
facilitate crystallization.
Our results demonstrate that, in the absence of other
eukaryotic proteins, the BCCL2 protein forms dimers.
Thus, the B-box 2 and coiled-coil domains, as well as
the adjacent L2 region, are sufficient for TRIM5 dimeri-
zation. Neither of the terminal domains (i.e., RING or
B30.2(SPRY)) is required for efficient dimerization. The
estimates of the secondary structure content of the
BCCL2 protein at different temperatures are consistent
with predictions that the coiled-coil domain of TRIM
proteins is mostly alpha helical [65-67]. Exposure to
45°C resulted in a dissociation of the dimer and a
decrease in the helicity of the protein. The integrity of
the dimer interface and that of a subset of the alpha-
helical structures on TRIM5 may be interconnected.
Such a situation might be expected if dimeric contacts
exist along the exposed surface of the alpha helices of
each subunit of the dimer.
The BCCL2 dimers formed higher-order structures.
Recently it has been reported that the full-length rhesus
monkey TRIM5a protein forms dimers, trimers, hexam-
ers and multimers of higher complexity in mammalian
cells; the hexameric form in particular appeared to be
the most abundant multimer [30]. TRIM5a multimeri-
zation does not involve disulfide bonds and is not
affected by infection with restriction-sensitive viruses
[30]. The formation of the functional TRIM5 higher-
order oligomers depends upon specific B-box 2 amino
acid residues [16,26], several of which were altered in
the BCCL2 protein without apparent disruption of the
higher-order oligomerization. However, multiple
changes in the B-box 2 surface did decrease the amount
of large BCCL2 aggregates. This allowed more homoge-
neous preparations of a BCCL2 variant, LLER, to be
analyzed by electron microscopy. Single-particle analysis
revealed that the lower-molecular-weight form of LLER
consisted of approximately 10-nm spheres. These LLER
forms likely represent dimers; consistent with this, many
examples of complexes consisting of two anti-His6 anti-
bodies bound to a single LLER sphere were evident. The
TRIM5 coiled coil, which is approximately 100 amino
acid residues in length, could not be accommodated in
these 10-nm spheres as a linear, rod-like structure; the
existence of insertions at specific locations in the coiled
coil regions of TRIM5 variants is consistent with the
Figure 10 Trypsin sensitivity of TRIM5a-21R and LLER proteins.
The TRIM5a-21R and LLER proteins were incubated at 37°C with a
1:150 (weight/weight) solution of trypsin in 25 mM bicarbonate
buffer, pH 8 for the indicated times. The reaction was stopped by
adding soybean trypsin inhibitor (STI) and the reaction mixtures
were boiled in Laemmli buffer. The mixtures were then analyzed by
SDS-PAGE and the gels were stained with Coomassie Blue.
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Page 11 of 14possibility that the coiled coil bends or folds back upon
itself. The higher molecular weight LLER complexes
formed C-shaped structures, with an appendage pro-
truding from the convex side of the arc. The size of
these structures is larger than that expected for a dimer,
and possibly represents a pentamer or hexamer. We do
not know if these higher-order structures are biologi-
cally relevant; it may be that the TRIM5a domains
(RING and B30.2(SPRY)) not included in the BCCL2
construct influence higher-order self-association either
quantitatively or qualitatively. Future work will explore
these issues.
Conclusions
The central core of TRIM5a, consisting of the B-box 2,
coiled coil and L2 linker region, forms dimers that are
largely alpha helical. The melting of the alpha-helical
structure of this TRIM5a core was biphasic, with one
transition at 42°C associated with a loss of dimerization,
and a second transition at 80°C.
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